Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 26:13:1002034.
doi: 10.3389/fimmu.2022.1002034. eCollection 2022.

Global research trends on precision cancer medicine-related rashes (2008-2021): A bibliographic study

Fangmin Zhao  1 , Rui Yu  1 , Shuyi Chen  2 , Shuya Zhao  1 , Lin Sun  1 , Zeting Xu  1 , Yao Zhang  1 , Shuying Dai  1 , Gaochenxi Zhang  2 , Qijin Shu  2
Affiliations

Global research trends on precision cancer medicine-related rashes (2008-2021): A bibliographic study

Fangmin Zhao et al. Front Immunol. .

Abstract

Background: Precision cancer medicine-related rashes are a kind of skin and mucous lesions caused by precision therapy. More and more evidences indicated that such events should not be ignored in the course of anti-tumor therapy. Since cancer treatment entered the "Precision Era", there has been a rapid increase in this field. However, there was few bibliometric studies to provide an overall review of this field. This study aims to evaluate the literature output and trends in researches on precision cancer medicine-related rashes from a global perspective.

Methods: Collected publications on precision cancer medicine-related rashes from the Web of Science Core Collection database, which were limited to articles and reviews in English. Microsoft Excel, VOS viewer and CiteSpace V were used for quantitative and visual analysis.

Results: A total of 1,229 papers were identified. From 2008 to 2021, annual publications increased year by year. The United States published the most papers in this field (44.9%) and ranking first in citation frequency (19,854 times) and H-index (69). The University of Texas system ranks first with 98 papers published. Lacouture M.E and Robert C were the principal investigators. Cancers has the largest number of articles published, with 70 articles. In recent years, there have been research hotspots related to immunotherapy, including ipilimumab, immunotherapy, tumor microenvironment, association, checkpoint inhibitor, and cutaneous adverse event.

Conclusion: Precision cancer medicine-related rashes are a hot research topic in oncology. The number of relevant publications will increase dramatically. "Checkpoint inhibitors", "skin adverse events", "associations" and "tumor microenvironment" may become research hotspots in the future.

Keywords: bibliometric analysis; checkpoint inhibitors; precision cancer medicine; rash; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flowchart for the selection of publications included in this study.
Figure 2
Figure 2
Trend of the number of articles published annually and the total amount of citations of annual articles.
Figure 3
Figure 3
(A) The changing trend of the annual publication counts in the top 10 countries. (B) The country citation network visualization map generated by VOS viewer (version5.8 R3). USA, The United States of America.
Figure 4
Figure 4
(A) The institutions’ collaboration network visualization map generated by VOS viewer (version5.8 R3) (B) The institutions’ citation network visualization map generated by VOS viewer (version5.8 R3).
Figure 5
Figure 5
(A) The authors’ collaboration network visualization map generated by VOS viewer (version5.8 R3). (B) The authors’ co-citation network visualization map generated by VOS viewer (version5.8 R3).
Figure 6
Figure 6
A dual-map overlay of the relevant journals generated by CiteSpace V (version5.8 R3).
Figure 7
Figure 7
The top 25 references with the strongest citation. (The green line segment represents the time interval, and the red line segment represents the active time).
Figure 8
Figure 8
(A) The network visualization map of keywords generated by VOS viewer (version5.8 R3). (B) The visualization map of keywords over time by VOS viewer (version5.8 R3).
Figure 9
Figure 9
(A) Timeline view of keywords from publications generated by CiteSpace V (version5.8 R3). (B) The top 25 keywords with the strongest citation bursts of publications (The green line segment represents the time interval, and the red line segment represents the active time).
See this image and copyright information in PMC

References

    1. Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R. Review of precision cancer medicine: Evolution of the treatment paradigm. Cancer Treat Rev (2020) 86:102019. doi: 10.1016/j.ctrv.2020.102019 - DOI - PMC - PubMed
    1. Prasad V, Fojo T, Brada M. Precision oncology: origins, optimism, and potential. Lancet Oncol (2016) 17(2):e81–e6. doi: 10.1016/s1470-2045(15)00620-8 - DOI - PubMed
    1. Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro Carpeno J, et al. Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: Nivolumab versus docetaxel in previously treated non-Small-Cell lung cancer. J Clin Oncol: Off J Am Soc Clin Oncol (2021) 39(7):723–33. doi: 10.1200/jco.20.01605 - DOI - PMC - PubMed
    1. van den Bulk J, Verdegaal EM, de Miranda NF. Cancer immunotherapy: Broadening the scope of targetable tumours. Open Biology (2018) 8(6):180037. doi: 10.1098/rsob.180037 - DOI - PMC - PubMed
    1. Lacouture M, Sibaud V. Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol (2018) 19(S1):31–9. doi: 10.1007/s40257-018-0384-3 - DOI - PMC - PubMed

Publication types